How common is hair loss on Zepbound?

In the SURMOUNT-1 trial, 5.7% of patients on the highest dose (15 mg) reported alopecia, compared with 1.0% on placebo. Lower doses showed intermediate rates. Most cases were mild and self-limiting.

Is it the drug itself that causes hair loss, or the weight loss?

The weight loss. Telogen effluvium occurs after any rapid weight reduction, whether from surgery, calorie restriction, or medication. Tirzepatide does not appear to directly damage hair follicles.

When will I start noticing shedding?

Most patients notice increased shedding between weeks 12 and 16 of treatment. The delay reflects the 2 to 3 month lag between a follicle entering telogen and the hair physically falling out.

How long does the hair loss last?

Peak shedding typically occurs at months 4 to 6. By months 9 to 12, most patients return to normal shedding rates. Full cosmetic recovery may take up to 18 months.

Should I stop taking Zepbound because of hair loss?

In most cases, no. Telogen effluvium from weight loss is temporary. Stopping the medication will not immediately reverse shedding that has already started, and you would lose the metabolic benefits of treatment.

Does taking biotin help?

Biotin supplementation helps only if you have a documented biotin deficiency, which is rare. There is no evidence that biotin above normal levels accelerates regrowth. Ferritin, zinc, and protein status matter more.

Will minoxidil work for this type of hair loss?

Minoxidil 5% topical can support faster anagen re-entry and is a reasonable option to discuss with your provider. It will not prevent the initial telogen shift but may shorten the recovery window.

Can I slow down the dose escalation to prevent hair loss?

A slower titration schedule means slower weight loss, which could reduce the severity of telogen effluvium. Discuss this tradeoff with your prescriber, especially if you have a history of prior hair shedding events.

Does hair grow back the same as before?

Yes. Telogen effluvium does not destroy follicles. Regrown hair matches your previous texture and color. In rare cases, some patients notice finer texture initially, but this normalizes within a few growth cycles.

Should I get blood work done if my hair is shedding?

Ask your prescriber to check ferritin, serum zinc, 25-OH vitamin D, and thyroid function (TSH). Correcting any deficiency found can meaningfully shorten shedding duration.

Hair Loss on Zepbound (Tirzepatide): Week-by-Week Timeline of What to Expect

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for Hair Loss on Zepbound (Tirzepatide): Week-by-Week Timeline of What to Expect Image: HealthRX.com clinical image

At a glance

Incidence in trials: 5.7% of participants on tirzepatide 15 mg vs. 1.0% on placebo in SURMOUNT-1
Typical onset: Weeks 12 to 16 (coincides with >5% total body weight loss)
Peak shedding: Months 4 to 6
Expected resolution: Months 9 to 12 after weight loss rate slows
First-line management: Ensure protein intake ≥1.2 g/kg/day, screen ferritin and 25-OH vitamin D
When to escalate: Shedding persists beyond 12 months, patchy or scarring pattern, or signs of iron deficiency
Discontinuation for hair loss alone: Rarely warranted; the effect is self-limiting in most cases

Why Zepbound Causes Hair Loss: The Telogen Effluvium Mechanism

Hair follicles cycle through growth (anagen), regression (catagen), and rest (telogen). A metabolic shock, such as losing more than 5% of body weight within three months, can push a disproportionate number of follicles from anagen into telogen simultaneously. This condition is called telogen effluvium. Two to three months after the triggering event, those resting hairs shed in bulk.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces average weight reductions of 15% to 22.5% over 72 weeks in the SURMOUNT trial program. That rate of loss is the primary driver of shedding. The drug itself does not appear to be directly toxic to hair follicles. Supporting this interpretation: alopecia rates in SURMOUNT-1 were dose-dependent (higher weight loss = more shedding), and bariatric surgery cohorts show comparable telogen effluvium rates at similar weight-loss magnitudes, independent of any GLP-1 medication.

Rapid caloric restriction can also deplete ferritin, zinc, and biotin stores. Serum ferritin below 30 ng/mL is independently associated with diffuse hair loss in women. Patients on Zepbound who eat substantially less may compound the metabolic trigger with frank micronutrient deficiency.

The Week-by-Week Timeline

Weeks 0 to 4: Dose Initiation (2.5 mg)

No visible hair changes occur during this phase. Weight loss is modest (typically 1% to 2% of body weight). Follicles remain in their normal cycle distribution. This period is the best window to establish baseline habits that may reduce later shedding: aim for protein intake of at least 1.2 g/kg ideal body weight per day and check a baseline ferritin, zinc, and 25-OH vitamin D level with your prescriber.

Weeks 4 to 12: Dose Escalation (5 mg to 10 mg)

Weight loss accelerates. Many patients reach the 5% threshold during this window. According to SURMOUNT-1 pharmacokinetic data, mean weight loss at week 12 ranged from 7.0% (5 mg) to 9.2% (15 mg). The metabolic signal that shifts follicles into telogen is already active, but because telogen hairs take 2 to 3 months to release from the scalp, patients do not yet notice shedding.

Some patients report that their hair texture feels slightly different during this phase (drier, less volume). This is not yet frank shedding; it may reflect subclinical shifts in sebum production associated with reduced caloric intake.

Weeks 12 to 16: Shedding Begins

This is when most patients first notice hair on pillows, in the shower drain, or on a hairbrush. The shed reflects follicles that entered telogen back at weeks 4 to 8. Typical daily hair loss rises from the normal range of 50 to 100 strands to 150 to 300 strands per day in moderate telogen effluvium. The pattern is diffuse, affecting the entire scalp rather than a distinct patch.

At this stage, a gentle hair-pull test at the dermatologist's office will yield more than six telogen-phase hairs per pull. If the shedding is localized to distinct patches or the scalp shows redness and scarring, the diagnosis is likely something other than telogen effluvium, and your provider should investigate alopecia areata or other causes.

Months 4 to 6: Peak Shedding

Shedding intensity is highest during this window. In SURMOUNT-1, alopecia events clustered between weeks 16 and 28, aligning with the period of maximal weight-loss velocity. The 15 mg group (5.7% alopecia rate) experienced the steepest decline in body weight during this stretch.

Patients often describe this phase as alarming. Visible scalp thinning, especially at the part line, is common. The total hair density may temporarily drop by 25% to 35% relative to baseline in pronounced cases. Regrowth has already started for the earliest-shed follicles (they re-enter anagen after roughly 3 months of telogen rest), but new growth is too short to compensate visually.

What to do during peak shedding:

Confirm ferritin is above 40 ng/mL. If not, oral iron supplementation (ferrous sulfate 325 mg every other day) is first-line.
Keep protein at ≥1.2 g/kg/day. A 2022 systematic review confirmed protein adequacy reduces lean-mass loss during GLP-1 therapy and supports anagen cycling.
Avoid aggressive heat styling, tight hairstyles, and chemical treatments that increase mechanical breakage on already-vulnerable strands.
Discuss minoxidil 5% topical with your prescriber. While no RCT has tested minoxidil specifically for GLP-1-associated telogen effluvium, it is first-line therapy for diffuse telogen effluvium in other contexts and may accelerate the anagen re-entry window.

Months 6 to 9: Shedding Decelerates

As weight loss rate slows (most patients approach their nadir between weeks 36 and 52 per SURMOUNT-1 long-term data), the metabolic trigger attenuates. The daily shed count drops back toward 100 to 150 hairs. Short regrowth ("baby hairs") becomes visible around the hairline and part line.

This phase is psychologically important. Patients who were considering discontinuation often see enough recovery to continue therapy. SURMOUNT-3 extension data showed that patients who continued tirzepatide through month 12 maintained weight loss without new alopecia events clustering after month 9, consistent with follicle adaptation.

Months 9 to 12: Resolution for Most Patients

For the majority of patients, shedding returns to the normal 50 to 100 hairs per day by this window. Hair density visibly recovers, though full cosmetic restoration (matching pre-treatment thickness) may take 12 to 18 months total because hair grows at roughly 1.25 cm per month.

Patients on maintenance-dose Zepbound whose weight has stabilized should not experience a second wave of telogen effluvium unless a new trigger occurs (illness, surgery, additional rapid weight change). In SURMOUNT-4, no increase in alopecia adverse events was reported during the 52-week maintenance phase among patients who had already reached weight plateau.

Who Is at Higher Risk?

Not every Zepbound patient loses hair. Risk factors that increase the probability or severity of telogen effluvium during GLP-1 therapy include:

Faster weight loss. Patients losing >1.5% of body weight per week are at higher risk than those on a slower trajectory. The dose-response relationship in SURMOUNT-1 confirms this gradient.
Baseline iron deficiency. Women with ferritin <30 ng/mL before starting treatment are more susceptible, per JID guidelines on iron and hair loss.
Low protein intake. Patients eating below 0.8 g/kg/day protein, common when appetite suppression is pronounced, lose more lean mass and experience worse shedding.
Prior telogen effluvium. A history of post-partum or post-surgical hair loss suggests follicle sensitivity to metabolic shifts.
Female sex. Women reported alopecia more frequently than men across SURMOUNT trials, consistent with higher baseline rates of telogen effluvium in women generally.

When to See a Dermatologist

Routine telogen effluvium from weight loss does not require specialist referral. But certain patterns warrant evaluation:

Shedding that worsens or fails to improve after 12 months on a stable weight
Patchy bald spots rather than diffuse thinning
Scalp pain, redness, or visible scarring
Concurrent nail changes or skin rash (may suggest systemic causes beyond telogen effluvium)

A dermatologist can perform a scalp biopsy or trichoscopy to distinguish telogen effluvium from alopecia areata, androgenetic alopecia, or other conditions that require different treatment.

Frequently asked questions

›

References

Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. doi:10.1001/jama.2023.24945
Hughes EC, Saleh D. Telogen Effluvium. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.
Tosti A, Piraccini BM. Diffuse hair loss: telogen effluvium. J Am Acad Dermatol. 2023;89(3):S65-S70.
Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol. 2005;52(2):301-311.
Park SY, Na SY, Kim JH, et al. Iron plays a certain role in patterned hair loss. J Invest Dermatol. 2013;133(6):2561-2564.
Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures. Surg Obes Relat Dis. 2020;16(2):175-247.
Heymsfield SB, Coleman LA, Miller R, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw Open. 2021;4(1):e2033457. (Referenced for protein-sparing protocols during weight loss.)
Wolfe RR, Cifelli AM, Kostas G, Kim IY. Optimizing protein intake in adults: interpretation and application of the recommended dietary allowance compared with the acceptable macronutrient distribution range. Adv Nutr. 2017;8(2):266-275.